ClinicalTrials.gg
Active, not recruitingNCT03045029ADAPTUpdated Apr 2, 2026

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

An observational study in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Active, not recruiting at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by United Therapeutics · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 51 studies in Pulmonary Arterial Hypertension by United Therapeutics — 1 open to participants now, 3 under way, 1 of them phase 3. Pulmonary Arterial Hypertension · United Therapeutics.

Started
2017
with 4 others
Observational
6 of 51
none open now
Registered
41st of 51
by date

Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is one of 5 that started in 2017, is one of 6 observational ones, and was the 41st registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, or all of them as a file.
02

Study summary

This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • PAH
  • Oral Treprostiinil
  • Orenitram
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients are eligible if they have been receiving Orenitram for 182 or fewer days.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible for the registry if:

  1. The patient voluntarily gives to participate in the study.
  2. The patient must be at least 18 years of age or older.
  3. The patient is prescribed Orenitram (per the package insert indication), and plans to initiate therapy with this medication or has been receiving Orenitram for 182 or fewer days.
  4. The patient agrees to dosing, prostacyclin-related AE of interest record keeping, survey participation during designated time periods, and recording any medication changes, use, for the duration of the study.
  5. The patient has the ability to answer surveys and use the diary in English.
  6. The patient must have an email address and be willing to access the PRO Portal.

Exclusion criteria

EXCLUSION CRITERIA

Patients are ineligible for the registry if:

  1. The patient has previously received Orenitram for more than 182 days.
  2. The patient is currently participating in an drug or device study or has participated in a clinical study with an investigational product other than Orenitram in PAH within
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
78 Weeks
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Oral treprostinil

    Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients

    Drug: Oral treprostinil

Interventions

  • Sustained-release oral tablets for TID administration

    Also known as: Treprostinil diethanolamine, Treprostinil diolamine

06

What researchers measure

Primary outcomes

  1. Real-world use and tolerability of Orenitram in new starts and prostacyclin transition patients

    Time frame: Baseline to Week 78

Secondary outcomes

  1. To assess treatment-related outcomes during routine clinical care.

    eg, 6-Minute Walk Distance \[6MWD\], World Health Organization \[WHO\] Functional Class \[FC\]

    Time frame: Baseline to Week 78

  2. To observe the development, timing, severity, frequency, and treatment of prostacyclin-related adverse events (AEs) of interest

    Time frame: Baseline to Week 78

  3. Use of concomitant medications

    Time frame: Baseline to Week 78

  4. To evaluate information on clinical titration schedules implemented for transition to and from alternative prostacyclin-class therapies

    Time frame: Baseline to Week 78

  5. Healthcare resource utilization trends

    Time frame: Baseline to Week 78

  6. Health-related quality of life in PAH and treatment satisfaction

    Time frame: Baseline to Week 78

  7. To evaluate reasons for discontinuation of Orenitram

    Time frame: Baseline to Week 78

  8. To evaluate titration and dosing schedules of Orenitram

    Time frame: Baseline to Week 78

07

Study locations

41 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Mar 2027, 116 months after the start.

Of 85 observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 93. This study's planned 116 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2017
First posted
Feb 7, 2017
StartActual
Jul 18, 2017
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03045029
Responsible party
Sponsor
First posted
Feb 7, 2017
Start date
Jul 18, 2017
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Apr 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion